糖尿病风险表型与COVID-19严重程度和死亡风险的关联:一项动态系统综述与Meta分析的更新
本研究为动态系统综述与Meta分析的首次更新,纳入169篇观察性研究(约90万糖尿病患者),评估糖尿病相关风险表型与COVID-19严重程度及死亡风险的关联。结果显示,男性、高龄、入院血糖升高、慢性胰岛素使用及合并症等与COVID-19死亡风险升高相关,而慢性二甲双胍使用及eGFR升高呈负相关。
要点
- 肥胖、HbA1c 53-75 mmol/mol、心衰、肝病等与COVID-19死亡风险升高相关。
- 慢性GLP-1受体激动剂使用与死亡风险降低相关(SRR 0.83)。
- 现有COVID-19疫苗接种状态与严重程度降低相关(SRR 0.32)。
核心结论
- 糖尿病病程更重且合并基础疾病的个体,其COVID-19预后较病情较轻者更差。
研究设计与样本
- 动态系统综述与Meta分析,纳入观察性研究,检索截至2022年12月1日,共纳入169篇文章(147项新研究),基于约90万个体。
主要发现
- 共进行177项Meta分析(83项关于COVID-19死亡,94项关于严重程度)。
- 肥胖与COVID-19死亡相关(SRR 1.18,95%CI 1.04-1.34,n=21项研究)。
- HbA1c 53-75 mmol/mol(7-9%)与死亡相关(SRR 1.18,95%CI 1.06-1.32,n=8项研究)。
- 慢性GLP-1受体激动剂使用与死亡相关(SRR 0.83,95%CI 0.71-0.97,n=9项研究)。
- 现有COVID-19疫苗接种状态与严重程度相关(SRR 0.32,95%CI 0.26-0.38,n=3项研究)。
关键数值与推荐
- 慢性二甲双胍使用与COVID-19死亡风险呈负相关(原文未报告具体数值)。
- eGFR每增加10 ml/min/1.73 m²,死亡风险SRR 0.80(95%CI 0.71-0.90,n=6项研究)。
- 淋巴细胞计数每增加1×10⁹/l,死亡风险SRR 0.59(95%CI 0.40-0.86,n=6项研究)。
- 既往心力衰竭与死亡相关(SRR 1.33,95%CI 1.21-1.47,n=14项研究)。
- 既往肝病与死亡相关(SRR 1.40,95%CI 1.17-1.67,n=6项研究)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 纳入的研究为观察性研究,残余或未测量的混杂因素无法排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: To provide a systematic overview of the current body of evidence on high-risk phenotypes of diabetes associated with COVID-19 severity and death. METHODS: This is the first update of our recently published living systematic review and meta-analysis. Observational studies investigating phenotypes in individuals with diabetes and confirmed SARS-CoV-2 infection with regard to COVID-19-related death and severity were included. The literature search was conducted from inception up to 14 February 2022 in PubMed, Epistemonikos, Web of Science and the COVID-19 Research Database and updated using PubMed alert to 1 December 2022. A random-effects meta-analysis was used to calculate summary relative risks (SRRs) with 95% CIs. The risk of bias was evaluated using the Quality in Prognosis Studies (QUIPS) tool and the certainty of evidence using the GRADE approach. RESULTS: A total of 169 articles (147 new studies) based on approximately 900,000 individuals were included. We conducted 177 meta-analyses (83 on COVID-19-related death and 94 on COVID-19 severity). Certainty of evidence was strengthened for associations between male sex, older age, blood glucose level at admission, chronic insulin use, chronic metformin use (inversely) and pre-existing comorbidities (CVD, chronic kidney disease, chronic obstructive pulmonary disease) and COVID-19-related death. New evidence with moderate to high certainty emerged for the association between obesity (SRR [95% CI] 1.18 [1.04, 1.34], n=21 studies), HbA1c (53-75 mmol/mol [7-9%]: 1.18 [1.06, 1.32], n=8), chronic glucagon-like peptide-1 receptor agonist use (0.83 [0.71, 0.97], n=9), pre-existing heart failure (1.33 [1.21, 1.47], n=14), pre-existing liver disease (1.40 [1.17, 1.67], n=6), the Charlson index (per 1 unit increase: 1.33 [1.13, 1.57], n=2), high levels of C-reactive protein (per 5 mg/l increase: 1.07 [1.02, 1.12], n=10), aspartate aminotransferase level (per 5 U/l increase: 1.28 [1.06, 1.54], n=5), eGFR (per 10 ml/min per 1.73 m2 increase: 0.80 [0.71, 0.90], n=6), lactate dehydrogenase level (per 10 U/l increase: 1.03 [1.01, 1.04], n=7) and lymphocyte count (per 1×109/l increase: 0.59 [0.40, 0.86], n=6) and COVID-19-related death. Similar associations were observed between risk phenotypes of diabetes and severity of COVID-19, with some new evidence on existing COVID-19 vaccination status (0.32 [0.26, 0.38], n=3), pre-existing hypertension (1.23 [1.14, 1.33], n=49), neuropathy and cancer, and high IL-6 levels. A limitation of this study is that the included studies are observational in nature and residual or unmeasured confounding cannot be ruled out. CONCLUSIONS/INTERPRETATION: Individuals with a more severe course of diabetes and pre-existing comorbidities had a poorer prognosis of COVID-19 than individuals with a milder course of the disease. REGISTRATION: PROSPERO registration no. CRD42020193692. PREVIOUS VERSION: This is a living systematic review and meta-analysis. The previous version can be found at https://link.springer.com/article/10.1007/s00125-021-05458-8 FUNDING: The German Diabetes Center (DDZ) is funded by the German Federal Ministry of Health and the Ministry of Culture and Science of the State North Rhine-Westphalia. This study was supported in part by a grant from the German Federal Ministry of Education and Research to the German Center for Diabetes Research (DZD).
引用
- Schlesinger S, Lang A, Christodoulou N, et al. Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis. Diabetologia. 2023. PMID: 37204441. doi:10.1007/s00125-023-05928-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。